tranexamic acid has been researched along with Myeloproliferative Disorders in 1 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appelmann, I | 1 |
| Kreher, S | 1 |
| Parmentier, S | 1 |
| Wolf, HH | 1 |
| Bisping, G | 1 |
| Kirschner, M | 1 |
| Bergmann, F | 1 |
| Schilling, K | 1 |
| Brümmendorf, TH | 1 |
| Petrides, PE | 1 |
| Tiede, A | 1 |
| Matzdorff, A | 1 |
| Griesshammer, M | 1 |
| Riess, H | 1 |
| Koschmieder, S | 1 |
1 review available for tranexamic acid and Myeloproliferative Disorders
| Article | Year |
|---|---|
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis
Topics: Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Blood Loss, Surgical; Blood Transf | 2016 |